KRAS and lung carcinoma: Importantly, BCL6 was functionally required for KRAS-mutant lung tumorigenesis and tumor growth, as the genetic or pharmacological inhibition of BCL6 significantly impeded the growth of KRAS-mutant lung cancer in preclinical mouse models.